Cargando…

Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib

Approximately 10–20% of patients demonstrate primary resistance to EGFR-TKIs, and different EGFR mutations vary in sensitivity to EGFR-TKIs. We report a case of a 78-year-old male with lung adenocarcinoma that EGFR L858R (AF = 1.32%) coexisting with EGFR S645C (AF = 7.13%) in his diagnosed tissues a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Li, Quan, Fei, Guo, Zhen, Lu, Zhongyu, Yang, Duoxia, Shi, Meiqi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576154/ https://www.ncbi.nlm.nih.gov/pubmed/37842288 http://dx.doi.org/10.2147/LCTT.S431252

Ejemplares similares

Miliary brain metastases from lung adenocarcinoma with EGFR (L858R) and CTNNB1 mutations
por: Kunishige, Michihiro, et al.
Publicado: (2023)

Durable Response to Osimertinib in a Chinese Patient with Metastatic Lung Adenocarcinoma Harboring a Rare EGFR L858R/D761Y Compound Mutation
por: Zhu, Yajie, et al.
Publicado: (2020)

Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas
por: Akahori, Daisuke, et al.
Publicado: (2021)

Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports
por: Li, Guangrui, et al.
Publicado: (2023)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab
por: Marrocco, Ilaria, et al.
Publicado: (2023)

Emerging a Novel VOPP1-EGFR Fusion Coexistent With T790M as an Acquired Resistance Mechanism to Prior Icotinib and Sensitive to Osimertinib in a Patient With EGFR L858R Lung Adenocarcinoma: A Case Report
por: Wang, Xia, et al.
Publicado: (2021)

Unusual metachronous lung adenocarcinomas harboring EGFR L858R/T790M mutations: A case report
por: Pei, Guotian, et al.
Publicado: (2020)

Leptomeningeal Metastatic L858R EGFR-mutant Lung Cancer: Prompt Response to Osimertinib in the Absence of T790M-mutation and Effective Subsequent Pulsed Erlotinib
por: Kanbour, Aladdin, et al.
Publicado: (2022)

Concomitant Mutations in EGFR 19Del/L858R Mutation and Their Association with Response to EGFR-TKIs in NSCLC Patients
por: Liang, Hengrui, et al.
Publicado: (2020)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma
por: Chiu, Chao-Hua, et al.
Publicado: (2015)

Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report
por: Zhao, Jing, et al.
Publicado: (2018)

3D radiomics predicts EGFR mutation, exon-19 deletion and exon-21 L858R mutation in lung adenocarcinoma
por: Liu, Guixue, et al.
Publicado: (2020)

Comparison of uncommon EGFR exon 21 L858R compound mutations with single mutation
por: Peng, Liang, et al.
Publicado: (2015)

Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon 21 L858R subsequent to treatment with EGFR-TKIs
por: He, Cheng, et al.
Publicado: (2019)

Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review
por: Zhang, Qianqian, et al.
Publicado: (2022)

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
por: Murano, Chihiro, et al.
Publicado: (2019)

Successful Treatment of EGFR-Mutant Synchronous SCLC and Lung Adenocarcinoma With Osimertinib
por: Batra, Ullas, et al.
Publicado: (2020)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer
por: Umelo, Ijeoma, et al.
Publicado: (2015)

Differential MicroRNA Expression between EGFR T790M and L858R Mutated Lung Cancer
por: Kim, Ji Yeon, et al.
Publicado: (2018)

A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma
por: Fawwaz, Muammar, et al.
Publicado: (2021)

First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation
por: Ishibashi, Naoya, et al.
Publicado: (2023)

Simultaneous Detection of the T790M and L858R Mutations in the EGFR Gene by Oligoribonucleotide Interference-PCR
por: Baba, Keisuke, et al.
Publicado: (2019)

Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation
por: Hou, Zhiwei, et al.
Publicado: (2023)

S645C Point Mutation Suppresses Degradation of EGFR to Promote Progression of Glioblastoma
por: Huang, Wenda, et al.
Publicado: (2022)

Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study
por: Zhou, Jinhua, et al.
Publicado: (2023)

Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, cis-G796s/cis-C797s by osimertinib, brigatinib, and bevacizumab combination therapy: A case report
por: Chang, Yuan, et al.
Publicado: (2022)

Durable response to afatinib in an advanced lung adenocarcinoma patient with an EGFR L858R/G729A compound mutation: a case report
por: Wu, Lige, et al.
Publicado: (2022)

Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?
por: Costa, D B, et al.
Publicado: (2007)

Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma
por: Liu, Yang, et al.
Publicado: (2019)

EGFR‐mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib
por: Hara, Reina, et al.
Publicado: (2021)

Lung adenocarcinoma in a patient with a cis EGFR L858R‐K860I doublet mutation identified using NGS‐based profiling test: Negative diagnosis on initial companion test and successful treatment with osimertinib
por: Onozawa, Hiroto, et al.
Publicado: (2020)

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
por: Wu, Hong, et al.
Publicado: (2015)

Osimertinib Resistance With a Novel EGFR L858R/A859S/Y891D Triple Mutation in a Patient With Non-Small Cell Lung Cancer: A Case Report
por: Yang, Yanli, et al.
Publicado: (2020)

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
por: Zheng, Lin-Peng, et al.
Publicado: (2018)

Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial
por: Zhou, Qing, et al.
Publicado: (2016)

Comparison of therapeutic effects of EGFR‐tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function
por: Zhou, Juan, et al.
Publicado: (2017)

YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR(L858R, T790M)‐mutant resistance in vitro and in vivo
por: Zhang, Zhang, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i7unkusaof8e4hj3a7rotpv0ec